Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

Non-Small-Cell Lung Cancer (NSCLC) is a poorly chemosensitive tumor and targeted therapies are only used for about 15% of patients where a specific driving and druggable lesion is observed (EGFR, ALK, ROS). KRAS is one of the most frequently mutated genes in NSCLC and patients harboring these mutati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Autores principales: Caiola, Elisa, Frapolli, Roberta, Tomanelli, Michele, Valerio, Rossana, Iezzi, Alice, Garassino, Marina C., Broggini, Massimo, Marabese, Mirko
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5772438/
https://ncbi.nlm.nih.gov/pubmed/29343688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-18900-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares